OBJECTIVES: The purpose of this study was to evaluate procedural and 1-year clinical and echocardiographic outcomes of patients treated with tricuspid edge-to-edge repair. BACKGROUND: Transcatheter edge-to-edge repair has been successfully performed in selected patients with symptomatic tricuspid regurgitation (TR) and high risk for surgery, but outcome data are sparse. METHODS: This analysis of the multicenter international TriValve (Transcatheter Tricuspid Valve Therapies) registry included 249 patients with severe TR treated with edge-to-edge repair in compassionate and/or off-label use. Clinical and echocardiographic outcomes were prospectively collected and retrospectively analyzed. RESULTS: In 249 patients (mean age 77 ± 9 years; European System for Cardiac Operative Risk Evaluation II score 6.4% [interquartile range: 3.9% to 13.9%]), a successful procedure with TR reduction to grade ≤2+ was achieved in 77% by placement of 2 ± 1 tricuspid clips. Concomitant treatment of severe TR and mitral regurgitation was performed in 52% of patients. At 1-year follow-up, significant and durable improvements in TR severity (TR ≤2+ in 72% of patients) and New York Heart Association functional class (≤II in 69% of patients) were observed. All-cause mortality was 20%, and the combined rate of mortality and unplanned hospitalization for heart failure was 35%. Predictors of procedural failure included effective regurgitant orifice area, tricuspid coaptation gap, tricuspid tenting area, and absence of central or anteroseptal TR jet location. Predictors of 1-year mortality were procedural failure, worsening kidney function, and absence of sinus rhythm. CONCLUSIONS: Transcatheter tricuspid edge-to-edge repair can achieve TR reduction at 1 year, resulting in significant clinical improvement. Predictors of procedural failure and 1-year mortality identified here may help select patients who will benefit most from this therapy.
OBJECTIVES: The purpose of this study was to evaluate procedural and 1-year clinical and echocardiographic outcomes of patients treated with tricuspid edge-to-edge repair. BACKGROUND: Transcatheter edge-to-edge repair has been successfully performed in selected patients with symptomatic tricuspid regurgitation (TR) and high risk for surgery, but outcome data are sparse. METHODS: This analysis of the multicenter international TriValve (Transcatheter Tricuspid Valve Therapies) registry included 249 patients with severe TR treated with edge-to-edge repair in compassionate and/or off-label use. Clinical and echocardiographic outcomes were prospectively collected and retrospectively analyzed. RESULTS: In 249 patients (mean age 77 ± 9 years; European System for Cardiac Operative Risk Evaluation II score 6.4% [interquartile range: 3.9% to 13.9%]), a successful procedure with TR reduction to grade ≤2+ was achieved in 77% by placement of 2 ± 1 tricuspid clips. Concomitant treatment of severe TR and mitral regurgitation was performed in 52% of patients. At 1-year follow-up, significant and durable improvements in TR severity (TR ≤2+ in 72% of patients) and New York Heart Association functional class (≤II in 69% of patients) were observed. All-cause mortality was 20%, and the combined rate of mortality and unplanned hospitalization for heart failure was 35%. Predictors of procedural failure included effective regurgitant orifice area, tricuspid coaptation gap, tricuspid tenting area, and absence of central or anteroseptal TR jet location. Predictors of 1-year mortality were procedural failure, worsening kidney function, and absence of sinus rhythm. CONCLUSIONS: Transcatheter tricuspid edge-to-edge repair can achieve TR reduction at 1 year, resulting in significant clinical improvement. Predictors of procedural failure and 1-year mortality identified here may help select patients who will benefit most from this therapy.
Authors: Sylvia Otto; Marija Velichkov; Ali Hamadanchi; P Christian Schulze; Sven Moebius-Winkler Journal: Cardiol J Date: 2021-05-04 Impact factor: 2.737
Authors: Mirjam G Winkel; Nicolas Brugger; Omar K Khalique; Christoph Gräni; Adrian Huber; Thomas Pilgrim; Michael Billinger; Stephan Windecker; Rebecca T Hahn; Fabien Praz Journal: Front Cardiovasc Med Date: 2020-05-05
Authors: Akram Kawsara; Fahad Alqahtani; Vuyisile T Nkomo; Mackram F Eleid; Sorin V Pislaru; Charanjit S Rihal; Rick A Nishimura; Hartzell V Schaff; Juan A Crestanello; Mohamad Alkhouli Journal: J Am Heart Assoc Date: 2021-01-05 Impact factor: 5.501
Authors: Adam Witkowski; Dariusz Dudek; Stanisław Bartuś; Wojciech Wojakowski; Andrzej Gackowski; Marek Grygier; Mariusz Kuśmierczyk; Miłosz J Jaguszewski; Ewa Kowalik; Katarzyna Bondaryk; Maciej Niewada; Piotr Przygodzki; Michał Jakubczyk Journal: Cardiol J Date: 2021-10-21 Impact factor: 3.487
Authors: Antonio Mangieri; Matteo Pagnesi; Damiano Regazzoli; Alessandra Laricchia; Edwin Ho; Ythan Goldberg; Mei Chau; Francesco Gallo; Andrea Fisicaro; Arif Khokhar; Antonio Colombo; Francesco Giannini; Azeem Latib Journal: Front Cardiovasc Med Date: 2020-10-14
Authors: Fabian Schipmann; Marwin Bannehr; Valentin Hähnel; Victoria Dworok; Jonathan Nübel; Christoph Edlinger; Michael Lichtenauer; Michael Haase; Michael Zänker; Christian Butter; Anja Haase-Fielitz Journal: Diseases Date: 2022-03-16